Objective：To investigate the effects of Salvia Miltiorrhiza Liguspyragine Hydrochloride and Glucose Injection（参芎葡萄糖注射液,SLGI） on the expression of platelet membrane receptors proteinase-activated receptor-1...Objective：To investigate the effects of Salvia Miltiorrhiza Liguspyragine Hydrochloride and Glucose Injection（参芎葡萄糖注射液,SLGI） on the expression of platelet membrane receptors proteinase-activated receptor-1（PAR1） and proteinase-activated receptor-4（PAR4） in end-stage renal disease（ESRD） patients on chronic haemodialysis（HD）.Methods：Eighty-six ESRD patients on HD（treated group） were treated with SLGI,7 days as one therapeutic course,for two successive courses.The previous therapies were unchanged.Flow cytometry was used to assess the expression of platelet PAR1 and PAR4 in the patients,and turbidity method was used to determine the platelet maximum aggregation rate（MAR）.Meanwhile,renal function was measured.The final data were compared with those before treatment and with those in the normal control group（54 healthy subjects）.Results：Compared with the normal control group,the expressions of PAR1 and PAR4 and platelet MAR in ESRD patients on HD was significantly higher before treatment（P=0.001,P=0.006, and P=0.008）;after treatment with SLGI,the above indices in patients were remarkably decreased（P=0.036 and P=0.046）,except PAR4（P=0.067）,but still higher than those in the normal control group,however,it was not statistically significant.Conclusions：（1） The overexpression of PAR1 and PAR4 might lead to increased platelet aggregation and this could be one of the reasons for the thrombotic events in ESRD patients on HD.（2） SLGI was able to down-regulate the expression of PAR1 in ESRD patients on HD,improve platelet function,and regulate platelet activation.展开更多
目的观察奥扎格雷联合参芎葡萄糖注射液治疗脑梗死的疗效及安全性。方法 2011年1月至2015年12月收治的脑梗死患者123例,按照随机随机数字表法分成两组。对照组61例,在常规治疗基础上加用参芎葡萄糖注射液。治疗组62例,在对照组的基础上...目的观察奥扎格雷联合参芎葡萄糖注射液治疗脑梗死的疗效及安全性。方法 2011年1月至2015年12月收治的脑梗死患者123例,按照随机随机数字表法分成两组。对照组61例,在常规治疗基础上加用参芎葡萄糖注射液。治疗组62例,在对照组的基础上加用奥扎格雷注射液,比较两组临床疗效。结果治疗组美国国立卫生研究院卒中量表(National Institute of Health stroke scale,NIHSS)、日常生活能力译分(ADL)均优于对照组(P<0.05,P<0.01);治愈率与有效率亦高于对照组(P<0.05,P<0.01);两组安全性方面差异无统计学意义(P>0.05)。结论奥扎格雷联合参芎葡萄糖注射液在治疗脑梗死方面疗效较单用参芎葡萄糖注射液更好,且安全性无差异。展开更多
基金Supported by the National Natural Science Foundation of China (No.30572441)
文摘Objective：To investigate the effects of Salvia Miltiorrhiza Liguspyragine Hydrochloride and Glucose Injection（参芎葡萄糖注射液,SLGI） on the expression of platelet membrane receptors proteinase-activated receptor-1（PAR1） and proteinase-activated receptor-4（PAR4） in end-stage renal disease（ESRD） patients on chronic haemodialysis（HD）.Methods：Eighty-six ESRD patients on HD（treated group） were treated with SLGI,7 days as one therapeutic course,for two successive courses.The previous therapies were unchanged.Flow cytometry was used to assess the expression of platelet PAR1 and PAR4 in the patients,and turbidity method was used to determine the platelet maximum aggregation rate（MAR）.Meanwhile,renal function was measured.The final data were compared with those before treatment and with those in the normal control group（54 healthy subjects）.Results：Compared with the normal control group,the expressions of PAR1 and PAR4 and platelet MAR in ESRD patients on HD was significantly higher before treatment（P=0.001,P=0.006, and P=0.008）;after treatment with SLGI,the above indices in patients were remarkably decreased（P=0.036 and P=0.046）,except PAR4（P=0.067）,but still higher than those in the normal control group,however,it was not statistically significant.Conclusions：（1） The overexpression of PAR1 and PAR4 might lead to increased platelet aggregation and this could be one of the reasons for the thrombotic events in ESRD patients on HD.（2） SLGI was able to down-regulate the expression of PAR1 in ESRD patients on HD,improve platelet function,and regulate platelet activation.
文摘目的观察奥扎格雷联合参芎葡萄糖注射液治疗脑梗死的疗效及安全性。方法 2011年1月至2015年12月收治的脑梗死患者123例,按照随机随机数字表法分成两组。对照组61例,在常规治疗基础上加用参芎葡萄糖注射液。治疗组62例,在对照组的基础上加用奥扎格雷注射液,比较两组临床疗效。结果治疗组美国国立卫生研究院卒中量表(National Institute of Health stroke scale,NIHSS)、日常生活能力译分(ADL)均优于对照组(P<0.05,P<0.01);治愈率与有效率亦高于对照组(P<0.05,P<0.01);两组安全性方面差异无统计学意义(P>0.05)。结论奥扎格雷联合参芎葡萄糖注射液在治疗脑梗死方面疗效较单用参芎葡萄糖注射液更好,且安全性无差异。
